EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nintedanib Lacks Efficacy in a Spirometry‐Confirmed and Bleomycin‐Induced Mouse Model of Idiopathic Pulmonary Fibrosis

Jamal Bousamaki, Grzegorz Maciag, Asbjørn Graver Petersen, Stefanie H Korntner, Stine Marie Jansen, Susanne E Pors, Linn Salto Mamsen, Silas A Rasmussen, Casper Gravesen Salinas, Louise Humle Kruse, Michael Feigh, Ulf Simonsen iD und 1 weitere

Basic & Clinical Pharmacology & Toxicology · 2026-04 · 138 (4)

DOI: 10.1111/bcpt.70220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 13.03.2026. Verfasst von Jamal Bousamaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Gubra A/S, Hørsholm, Denmark. Hauptthemen laut MEDLINE: Indoles, Idiopathic Pulmonary Fibrosis, Protein Kinase Inhibitors. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovation Fund Denmark, Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nintedanib, a multitargeted tyrosine kinase inhibitor, is approved for idiopathic pulmonary fibrosis (IPF) for its ability to slow lung function decline. This study systematically evaluated the effects of nintedanib across three independent treatment intervention studies in the single‐dose bleomycin (BLEO) mouse model of IPF. In each study, male C57BL/6J mice received a single intratracheal instillation of BLEO ( n = 15–18) or saline ( n = 10). Animals were randomised and stratified by body weight, and treatment assignment was assessed using noninvasive whole‐body plethysmography 6 days after BLEO administration. BLEO‐IPF mice were administered (PO, BID) vehicle, nintedanib (50 or 60 mg/kg), or an activin receptor‐like kinase 5 inhibitor (ALK5i, SB525334, 60 mg/kg) for up to 21 days. In all studies, nintedanib consistently failed to improve lung health, as evaluated by lung function tests, biochemistry, histology and RNA sequencing. Plasma concentrations of nintedanib showed no correlation to any efficacy endpoint applied. Lung transcriptome signatures in nintedanib‐treated BLEO‐IPF mice indicated upregulated mRNA expression of p‐glycoprotein, a known nintedanib efflux transporter, suggesting limited lung exposure of nintedanib in the model. In comparison, ALK5i significantly improved lung function and exhibited robust antifibrotic efficacy. Collectively, these findings challenge the use of nintedanib as a benchmarking drug in the single‐dose BLEO‐IPF mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesIdiopathic Pulmonary FibrosisProtein Kinase InhibitorsAnimalsBleomycinMaleMice, Inbred C57BLDisease Models, AnimalLungMiceReceptor, Transforming Growth Factor-beta Type IImidazolesRespiratory Function TestsQuinoxalines

Stichwörter der Autor:innen

ALK5 inhibitoridiopathic pulmonary fibrosis modelnintedanib

Substanzen

nintedanibIndolesBleomycinReceptor, Transforming Growth Factor-beta Type IProtein Kinase Inhibitors6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxalineTgfbr1 protein, mouseImidazolesQuinoxalines

Autor:innen und Institutionen

  • Gubra A/S, Hørsholm, Denmark.
  • Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Faculty of Health, Aarhus University, Aarhus, Denmark.

ORCID-Profile: Ulf Simonsen, Henrik H Hansen

Förderung

  • Innovation Fund Denmark
  • Innovationsfonden

Zitieren

APA

Bousamaki, J., Maciag, G., Petersen, A. G., Korntner, S. H., Jansen, S. M., Pors, S. E., Mamsen, L. S., Rasmussen, S. A., Salinas, C. G., Kruse, L. H., Feigh, M., Simonsen, U., & Hansen, H. H. (2026). Nintedanib Lacks Efficacy in a Spirometry‐Confirmed and Bleomycin‐Induced Mouse Model of Idiopathic Pulmonary Fibrosis. Basic & Clinical Pharmacology & Toxicology, 138(4). https://doi.org/10.1111/bcpt.70220

Vancouver

Bousamaki J, Maciag G, Petersen AG, Korntner SH, Jansen SM, Pors SE, et al. Nintedanib Lacks Efficacy in a Spirometry‐Confirmed and Bleomycin‐Induced Mouse Model of Idiopathic Pulmonary Fibrosis. Basic & Clinical Pharmacology & Toxicology. 2026;138(4). doi:10.1111/bcpt.70220

BibTeX
@article{Bousamaki2026,
  author = {Bousamaki, Jamal and Maciag, Grzegorz and Petersen, Asbjørn Graver and Korntner, Stefanie H and Jansen, Stine Marie and Pors, Susanne E and Mamsen, Linn Salto and Rasmussen, Silas A and Salinas, Casper Gravesen and Kruse, Louise Humle and Feigh, Michael and Simonsen, Ulf and Hansen, Henrik H},
  title = {Nintedanib Lacks Efficacy in a Spirometry‐Confirmed and Bleomycin‐Induced Mouse Model of Idiopathic Pulmonary Fibrosis},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  volume = {138},
  number = {4},
  doi = {10.1111/bcpt.70220}
}
Kostenlos starten →